Rifaximin and nonabsorbable disaccharides for hepatic encephalopathy.
Mario
M
Guslandi
Alessandra
A
Cella
D003362:Cost-Benefit Analysis; D004187:Disaccharides / Q000191:economics / Q000627:therapeutic use*; D016527:Drug Costs; D005765:Gastrointestinal Agents / Q000191:economics / Q000627:therapeutic use*; D006501:Hepatic Encephalopathy / Q000188:drug therapy*; D006801:Humans; D018579:Patient Selection; D012294:Rifamycins / Q000191:economics / Q000627:therapeutic use*; D000078262:Rifaximin; D016896:Treatment Outcome
D004187:Disaccharides; D005765:Gastrointestinal Agents; D012294:Rifamycins; D000078262:Rifaximin